$RENB
RENOVARO INC. Stock $renb

$renb Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000173112224001578 Filed on October 10, 2024

Income Statement

Concept	2024 Q4	2024 Q2	2024
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.999M
YoY Change		69.45%
% of Gross Profit
Research & Development		$434.5K	$2.709M
YoY Change		-56.11%	-34.97%
% of Gross Profit
Depreciation & Amortization		$31.13K	$121.9K
YoY Change		55.65%	7.37%
% of Gross Profit
Operating Expenses		$5.464M	$81.64M
YoY Change		37.64%	111.74%
Operating Profit			-$81.64M
YoY Change			111.74%
Interest Expense		-$1.685M
YoY Change		547.98%
% of Operating Profit
Other Income/Expense, Net		$4.241M	$989.1K
YoY Change			-187.75%
Pretax Income		-$15.73M
YoY Change		-32.19%
Income Tax
% Of Pretax Income
Net Earnings		-$15.73M	-$80.65M
YoY Change		-32.19%	103.23%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.84
Diluted Earnings Per Share		-$0.11	-$0.84
COMMON SHARES
Basic Shares Outstanding	156.2M shares	147.5M shares	96.25M shares
Diluted Shares Outstanding			96.25M shares

Balance Sheet

Concept	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$220.5K	$220.5K
YoY Change	-88.4%	-88.4%
Cash & Equivalents	$220.5K
Short-Term Investments
Other Short-Term Assets	$668.9K	$668.9K
YoY Change	-4.44%	-4.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.998M	$1.998M
YoY Change	-22.13%	-23.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$482.1K	$1.752M
YoY Change	-5.28%	25.13%
Goodwill	$159.3M
YoY Change	1268.82%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$160.6M	$19.85K
YoY Change	190.89%
Total Long-Term Assets	$161.1M	$161.1M
YoY Change	189.1%	189.29%
TOTAL ASSETS
Total Short-Term Assets	$1.998M	$1.998M
Total Long-Term Assets	$161.1M	$161.1M
Total Assets	$163.1M	$163.1M
YoY Change	179.81%	179.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.449M	$9.449M
YoY Change	78.28%	78.28%
Accrued Expenses	$5.311M	$5.805M
YoY Change	634.45%	544.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.451M	$2.451M
YoY Change	-46.72%	-46.72%
Total Short-Term Liabilities	$30.31M	$30.31M
YoY Change	174.97%	175.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$231.4K	$842.4K
YoY Change	25.25%	5.3%
Total Long-Term Liabilities	$842.4K	$842.4K
YoY Change	8.61%	5.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.31M	$30.31M
Total Long-Term Liabilities	$842.4K	$842.4K
Total Liabilities	$31.15M	$31.15M
YoY Change	164.03%	164.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$324.7M
YoY Change	33.05%
Common Stock	$15.50K
YoY Change	143.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$132.0M	$132.0M
YoY Change
Total Liabilities & Shareholders Equity	$163.1M	$163.1M
YoY Change	179.81%	179.81%

Cashflow Statement

Concept	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$15.73M	-$80.65M
YoY Change	-32.19%	103.23%
Depreciation, Depletion And Amortization	$31.13K	$121.9K
YoY Change	55.65%	7.37%
Cash From Operating Activities	-$2.414M	-$10.97M
YoY Change	6.8%	-6.82%
INVESTING ACTIVITIES
Capital Expenditures	$23.55K	$70.43K
YoY Change	135.5%	136.55%
Acquisitions
YoY Change
Other Investing Activities	-$29.82K	-$1.190M
YoY Change
Cash From Investing Activities	-$53.37K	-$1.260M
YoY Change	433.7%	4132.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.467M	$10.52M
YoY Change	97.34%	132.94%
NET CHANGE
Cash From Operating Activities	-2.414M	-$10.97M
Cash From Investing Activities	-53.37K	-$1.260M
Cash From Financing Activities	2.467M	$10.52M
Net Change In Cash	-430.0	-$1.654M
YoY Change	-99.96%	-77.34%
FREE CASH FLOW
Cash From Operating Activities	-$2.414M	-$10.97M
Capital Expenditures	$23.55K	$70.43K
Free Cash Flow	-$2.437M	-$11.04M
YoY Change	7.37%	-6.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2023	us-gaap	Operating Expenses OperatingExpenses	38556891	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-81639296	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-38556891	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001527728
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024	RENB	Preferred Stock Converted To Common Stock Pursuant To Acquisition Of Gedi Cube PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-38758
CY2024	dei	Entity Registrant Name EntityRegistrantName	RENOVARO INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2559340
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	2080 Century Park East
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 906
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90067
CY2024	dei	City Area Code CityAreaCode	305
CY2024	dei	Local Phone Number LocalPhoneNumber	918-1980
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024	dei	Trading Symbol TradingSymbol	RENB
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	57193356	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	156193912	shares
CY2024	dei	Auditor Firm AuditorFirmId	3627
CY2024	dei	Auditor Name AuditorName	Sadler, Gibb & Associates, LLC
CY2024	dei	Auditor Location AuditorLocation	Draper, UT
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220467	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1874480	usd
CY2024Q2	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	1108247	usd
CY2023Q2	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	668929	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	690925	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1997643	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2565405	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	482121	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508989	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	30043	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2024Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	159330161	usd
CY2023Q2	us-gaap	Goodwill Goodwill	11640000	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	19849	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	21741	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1269633	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	913985	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	160649686	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55226402	usd
CY2024Q2	us-gaap	Assets Assets	163129450	usd
CY2023Q2	us-gaap	Assets Assets	58300796	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9448683	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5296823	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5311324	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	723173	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	295361	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	184733	usd
CY2024Q2	RENB	Contingent Consideration Liability Current ContingentConsiderationLiabilityCurrent	12310000	usd
CY2023Q2	RENB	Contingent Consideration Liability Current ContingentConsiderationLiabilityCurrent	0	usd
CY2024Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	245000	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	493553	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	193422	usd
CY2024Q2	RENB	Notes Payable Related Parties Net Current NotesPayableRelatedPartiesNetCurrent	2205996	usd
CY2023Q2	RENB	Notes Payable Related Parties Net Current NotesPayableRelatedPartiesNetCurrent	4624947	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	30309917	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11023098	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	842389	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	775587	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	842389	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	775587	usd
CY2024Q2	us-gaap	Liabilities Liabilities	31152306	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11798685	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155027245	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155027245	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63698144	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63698144	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	15504	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6371	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	456811911	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290554875	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-324679425	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244029253	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-170846	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29882	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	131977144	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46502111	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	163129450	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58300796	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24557608	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15318198	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2708829	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4165197	usd
CY2024	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	18960000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11640000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	121859	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	113496	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	81639296	usd
CY2024	RENB	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	4727473	usd
CY2023	RENB	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	0	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1303578	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024	RENB	Loss On Extinguishment Of Contingent Consideration Liability LossOnExtinguishmentOfContingentConsiderationLiability	0	usd
CY2023	RENB	Loss On Extinguishment Of Contingent Consideration Liability LossOnExtinguishmentOfContingentConsiderationLiability	-419182	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1011322	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	580344	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1019	usd
CY2024	RENB	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	-1423449	usd
CY2023	RENB	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	-126620	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	989124	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1127165	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-80650172	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-39684056	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96248090	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96248090	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56265362	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56265362	shares
CY2024	us-gaap	Profit Loss ProfitLoss	-80650172	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-39684056	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	140964	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-554	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80791136	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39683502	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	72618848	usd
CY2023	RENB	Stock Issued Pursuant To Warrants Exercised Value StockIssuedPursuantToWarrantsExercisedValue	1625000	usd
CY2023	RENB	Earnout Shares Issued Value EarnoutSharesIssuedValue	2762500	usd
CY2023	RENB	Shares Issued For Interest On Notes Payable Extension Value SharesIssuedForInterestOnNotesPayableExtensionValue	204392	usd
CY2023	RENB	Issuance Of Common Stock And Warrants Under Private Placement Offering Value IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingValue	4011822	usd
CY2023	RENB	Restricted Shares Issued For Services Rendered Value RestrictedSharesIssuedForServicesRenderedValue	228000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1200000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3535051	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-39684056	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	554	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46502111	usd
CY2024	RENB	Issuance Of Preferred Stock And Warrants In Private Placement IssuanceOfPreferredStockAndWarrantsInPrivatePlacement	2000000	usd
CY2024	RENB	Issuance Of Preferred Stock And Warrants For Conversion Of Note Payable IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable	2000001	usd
CY2024	RENB	Restricted Shares Issued For Services Rendered Value RestrictedSharesIssuedForServicesRenderedValue	4664190	usd
CY2024	RENB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	2341866	usd
CY2024	RENB	Issuance Of Common Stock And Warrants Under Private Placement Offering In Settlement Of Debt Value IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue	10576106	usd
CY2024	RENB	Shares Issuable For Settlement Of Contingent Consideration Value SharesIssuableForSettlementOfContingentConsiderationValue	3520027	usd
CY2024	RENB	Issuance Of Common Stock Pursuant To Acquisition Of Gedi Cube IssuanceOfCommonStockPursuantToAcquisitionOfGediCube	136001631	usd
CY2024	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	489000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	4673129	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-80650172	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-140964	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	131977144	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-80650172	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-39684056	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	121859	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	113496	usd
CY2024	RENB	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	4727473	usd
CY2023	RENB	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-0	usd
CY2024	RENB	Loss On Extinguishment Of Contingent Consideration Liabilities LossOnExtinguishmentOfContingentConsiderationLiabilities	-0	usd
CY2023	RENB	Loss On Extinguishment Of Contingent Consideration Liabilities LossOnExtinguishmentOfContingentConsiderationLiabilities	-419182	usd
CY2024	RENB	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	-1303578	usd
CY2024	RENB	Noncash Stockbased Compensation Expense NoncashStockbasedCompensationExpense	4673129	usd
CY2023	RENB	Noncash Stockbased Compensation Expense NoncashStockbasedCompensationExpense	3535051	usd
CY2024	RENB	Noncash Restricted Shares Issued For Services Rendered NoncashRestrictedSharesIssuedForServicesRendered	4664190	usd
CY2023	RENB	Noncash Restricted Shares Issued For Services Rendered NoncashRestrictedSharesIssuedForServicesRendered	228000	usd
CY2024	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	18960000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11640000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024	RENB	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	580605	usd
CY2023	RENB	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	348621	usd
CY2024	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1108247	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-46	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1082267	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1070249	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4057282	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3894955	usd
CY2024	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-54060	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	11284	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-27224	usd
CY2024	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4769268	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-578809	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10971430	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11774549	usd
CY2024	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1255600	usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	-0	usd
CY2024	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	65851	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70430	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29774	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1260179	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29774	usd
CY2024	RENB	Repayments Of Finance Agreement RepaymentsOfFinanceAgreement	870073	usd
CY2023	RENB	Repayments Of Finance Agreement RepaymentsOfFinanceAgreement	1121767	usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	341865	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1625000	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4011823	usd
CY2024	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3770512	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4275151	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10517455	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4515056	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60141	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8395	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1654013	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7297662	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1874480	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9172142	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220467	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1874480	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	20128	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	352334	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024	RENB	Contingent Shares Issued Pursuant To Acquisition Agreement ContingentSharesIssuedPursuantToAcquisitionAgreement	0	usd
CY2023	RENB	Contingent Shares Issued Pursuant To Acquisition Agreement ContingentSharesIssuedPursuantToAcquisitionAgreement	2762500	usd
CY2024	RENB	Shares In Lieu Of Interest On Million Notes Payable Extension SharesInLieuOfInterestOnMillionNotesPayableExtension	0	usd
CY2023	RENB	Shares In Lieu Of Interest On Million Notes Payable Extension SharesInLieuOfInterestOnMillionNotesPayableExtension	204392	usd
CY2024	RENB	Finance Agreement Entered Into In Exchange For Prepaid Assets FinanceAgreementEnteredIntoInExchangeForPrepaidAssets	906834	usd
CY2023	RENB	Finance Agreement Entered Into In Exchange For Prepaid Assets FinanceAgreementEnteredIntoInExchangeForPrepaidAssets	1139875	usd
CY2024	RENB	Conversion Of Note Payable For Issuance Of Preferred Stock ConversionOfNotePayableForIssuanceOfPreferredStock	2000001	usd
CY2023	RENB	Conversion Of Note Payable For Issuance Of Preferred Stock ConversionOfNotePayableForIssuanceOfPreferredStock	0	usd
CY2024	RENB	Note Payable Settled Through Noncash Exercise Of Warrants NotePayableSettledThroughNoncashExerciseOfWarrants	2000000	usd
CY2023	RENB	Note Payable Settled Through Noncash Exercise Of Warrants NotePayableSettledThroughNoncashExerciseOfWarrants	0	usd
CY2024	RENB	Debt Discount Related To Convertible Promissory Notes DebtDiscountRelatedToConvertiblePromissoryNotes	339342	usd
CY2023	RENB	Debt Discount Related To Convertible Promissory Notes DebtDiscountRelatedToConvertiblePromissoryNotes	0	usd
CY2024	RENB	Common Shares Issued Upon Acquisition CommonSharesIssuedUponAcquisition	136001631	usd
CY2023	RENB	Common Shares Issued Upon Acquisition CommonSharesIssuedUponAcquisition	0	usd
CY2024	RENB	Contingent Consideration Issued Upon Acquisition ContingentConsiderationIssuedUponAcquisition	20557500	usd
CY2023	RENB	Contingent Consideration Issued Upon Acquisition ContingentConsiderationIssuedUponAcquisition	0	usd
CY2024	RENB	Common Shares Issued Upon Settlement Of Debt CommonSharesIssuedUponSettlementOfDebt	9582912	usd
CY2023	RENB	Common Shares Issued Upon Settlement Of Debt CommonSharesIssuedUponSettlementOfDebt	0	usd
CY2024	RENB	Earn Out Shares Issued In Settlement Of Contingent Liability EarnOutSharesIssuedInSettlementOfContingentLiability	3520027	usd
CY2023	RENB	Earn Out Shares Issued In Settlement Of Contingent Liability EarnOutSharesIssuedInSettlementOfContingentLiability	0	usd
CY2024	RENB	Options Issued In Settlement Of Debt OptionsIssuedInSettlementOfDebt	489000	usd
CY2023	RENB	Options Issued In Settlement Of Debt OptionsIssuedInSettlementOfDebt	0	usd
CY2024	RENB	Settlement Of Notes Payable SettlementOfNotesPayable	418503	usd
CY2023	RENB	Settlement Of Notes Payable SettlementOfNotesPayable	0	usd
CY2024Q2	RENB	Escrow Shares Remaining EscrowSharesRemaining	17414	shares
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zUyeFCYi1Mn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86B_zKw8wsgRetn9">Use of Accounting Estimates</span> </b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value of the contingent consideration liability, and the fair value of equity instruments issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zXAySCjPuzqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zivhDldXlM9l">Concentration of Credit Risk</span> –</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are held. As of June 30, 2024, and June 30, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2024Q2	RENB	In Process Research And Development InProcessResearchAndDevelopment	0	usd
CY2024Q2	us-gaap	Goodwill Goodwill	159330161	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2708829	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4165197	usd
CY2024Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	152837573	shares
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	63698144	shares
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17146315	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7949513	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-80650172	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-39684056	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	220467	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-324679425	usd
CY2024Q2	RENB	Working Capital Deficit WorkingCapitalDeficit	28312274	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1060461	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	973788	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	578340	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	464799	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	482121	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508989	usd
CY2024	us-gaap	Depreciation Depreciation	113563	usd
CY2023	us-gaap	Depreciation Depreciation	107321	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	30043	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8296	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6175	usd
CY2023Q2	RENB	Net Definitelife Intangible Assets NetDefinitelifeIntangibleAssets	39676	usd
CY2024	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	0	usd
CY2024	RENB	Net Definitelife Intangible Assets Amortization NetDefinitelifeIntangibleAssetsAmortization	-8296	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024	us-gaap	Finite Lived Intangible Assets Translation And Purchase Accounting Adjustments FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments	-1337	usd
CY2024Q2	RENB	Net Definitelife Intangible Assets NetDefinitelifeIntangibleAssets	30043	usd
CY2023Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	54251000	usd
CY2024	us-gaap	Indefinite Lived Intangible Assets Period Increase Decrease IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease	159464039	usd
CY2024	RENB	Indefinite Life Intangible Assets And Goodwill Amortization IndefiniteLifeIntangibleAssetsAndGoodwillAmortization	0	usd
CY2024	RENB	Indefinite Life Intangible Assets And Goodwill Impairment IndefiniteLifeIntangibleAssetsAndGoodwillImpairment	-54251000	usd
CY2024	us-gaap	Indefinite Lived Intangible Assets Translation And Purchase Accounting Adjustments IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments	-133878	usd
CY2024Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	159330161	usd
CY2022Q2	RENB	Net Definitelife Intangible Assets NetDefinitelifeIntangibleAssets	44268	usd
CY2023	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	-6175	usd
CY2023	us-gaap	Finite Lived Intangible Assets Translation And Purchase Accounting Adjustments FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments	1583	usd
CY2023Q2	RENB	Net Definitelife Intangible Assets NetDefinitelifeIntangibleAssets	39676	usd
CY2022Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	73211000	usd
CY2023	us-gaap	Indefinite Lived Intangible Assets Period Increase Decrease IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease	-18960000	usd
CY2023	us-gaap	Indefinite Lived Intangible Assets Translation And Purchase Accounting Adjustments IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments	0	usd
CY2023Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	54251000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7511	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7511	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7511	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7510	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	30043	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	18960000	usd
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11640000	usd
CY2017Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized.
CY2018Q2	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M14D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0514	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	554453	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	457876	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	334788	usd
CY2024Q2	RENB	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	79830	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	91005	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1335942	usd
CY2022Q2	us-gaap	Lessee Finance Sublease Residual Value Guarantee Description LesseeFinanceSubleaseResidualValueGuaranteeDescription	On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
CY2023Q2	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	139460	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	35540	usd
CY2023Q2	us-gaap	Liabilities Subject To Compromise Early Contract Termination Fees LiabilitiesSubjectToCompromiseEarlyContractTerminationFees	175000	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	383549	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	322447	usd
CY2024	us-gaap	Sublease Income SubleaseIncome	-0	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	352700	usd
CY2024	RENB	Operating Lease Rent Expenses OperatingLeaseRentExpenses	383549	usd
CY2023	RENB	Operating Lease Rent Expenses OperatingLeaseRentExpenses	-30253	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	380983	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	439519	usd
CY2023	RENB	Operating Lease Expenses OperatingLeaseExpenses	322447	usd
CY2023Q2	RENB	Cash Paid For The Termination Of Lease CashPaidForTheTerminationOfLease	439519	usd
CY2023	RENB	Accrual Payments Related To Termination Of Lease AccrualPaymentsRelatedToTerminationOfLease	77242	usd
CY2024	RENB	Interest Expense Related To Note Balance InterestExpenseRelatedToNoteBalance	245000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	231381	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1011322	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	580344	usd
CY2024Q2	RENB	Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets DeferredTaxAssetExcessTaxOverDepreciationFixedAssets	8258	usd
CY2023Q2	RENB	Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets DeferredTaxAssetExcessTaxOverDepreciationFixedAssets	8258	usd
CY2024Q2	RENB	Deferred Tax Asset Excess Tax Over Depreciation Patents DeferredTaxAssetExcessTaxOverDepreciationPatents	8415	usd
CY2023Q2	RENB	Deferred Tax Asset Excess Tax Over Depreciation Patents DeferredTaxAssetExcessTaxOverDepreciationPatents	8415	usd
CY2024Q2	RENB	Stockoptions Compensation StockoptionsCompensation	6672252	usd
CY2023Q2	RENB	Stockoptions Compensation StockoptionsCompensation	3885996	usd
CY2024Q2	RENB	Depreciation And Amortizations DepreciationAndAmortizations	188422	usd
CY2023Q2	RENB	Depreciation And Amortizations DepreciationAndAmortizations	152059	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	144191530	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	140547314	usd
CY2024Q2	RENB	Impairment Expense ImpairmentExpense	16188497	usd
CY2023Q2	RENB	Impairment Expense ImpairmentExpense	0	usd
CY2024Q2	RENB	Contingent Consideration Fair Value ContingentConsiderationFairValue	1410678	usd
CY2023Q2	RENB	Contingent Consideration Fair Value ContingentConsiderationFairValue	0	usd
CY2024Q2	RENB	Change In Tax Rate ChangeInTaxRate	0	usd
CY2023Q2	RENB	Change In Tax Rate ChangeInTaxRate	0	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	168668052	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	144602042	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-24066011	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-70341751	usd
CY2024	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	0	usd
CY2023	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	0	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	24066011	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	70341751	usd
CY2024	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2024	RENB	Excess Tax Benefit Over Depreciation Fixed Assets ExcessTaxBenefitOverDepreciationFixedAssets	8258	usd
CY2023	RENB	Excess Tax Benefit Over Depreciation Fixed Assets ExcessTaxBenefitOverDepreciationFixedAssets	8258	usd
CY2024	RENB	Excess Tax Benefit Over Depreciation Patents ExcessTaxBenefitOverDepreciationPatents	8415	usd
CY2023	RENB	Excess Tax Benefit Over Depreciation Patents ExcessTaxBenefitOverDepreciationPatents	8415	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	6672252	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3885996	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization	188422	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization	152059	usd
CY2024	RENB	Income Tax Expense Benefit Operating Loss Carryforwards IncomeTaxExpenseBenefitOperatingLossCarryforwards	144191530	usd
CY2023	RENB	Income Tax Expense Benefit Operating Loss Carryforwards IncomeTaxExpenseBenefitOperatingLossCarryforwards	140547314	usd
CY2024	RENB	Income Tax Expense Benefit Impairment Expense IncomeTaxExpenseBenefitImpairmentExpense	16188497	usd
CY2023	RENB	Income Tax Expense Benefit Impairment Expense IncomeTaxExpenseBenefitImpairmentExpense	0	usd
CY2024	RENB	Income Tax Expense Benefit Contingent Consideration Fair Value IncomeTaxExpenseBenefitContingentConsiderationFairValue	1410678	usd
CY2024	RENB	Deferred Income Tax Expense Change In Tax Rate DeferredIncomeTaxExpenseChangeInTaxRate	0	usd
CY2023	RENB	Deferred Income Tax Expense Change In Tax Rate DeferredIncomeTaxExpenseChangeInTaxRate	0	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	168668052	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	144602042	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	RENB	Common Stock Share Issued CommonStockShareIssued	155027245	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155027245	shares
CY2023Q2	RENB	Common Stock Share Issued CommonStockShareIssued	63698144	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63698144	shares
CY2024Q2	RENB	Common Stock Convertible Shares Issuable CommonStockConvertibleSharesIssuable	2189672	shares
CY2023Q2	us-gaap	Purchase Obligation PurchaseObligation	20000000	usd
CY2024	RENB	Settlement Of Debt SettlementOfDebt	1183560	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	50000	shares
CY2024Q1	RENB	Issuance Of Common Stock Under Private Placement Offering IssuanceOfCommonStockUnderPrivatePlacementOffering	344827	shares
CY2024Q1	RENB	Common Stock Par Value Private Placement CommonStockParValuePrivatePlacement	0.0001
CY2024Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1000000	usd
CY2023Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	525945	shares
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	341865	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	1200000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.53
CY2023Q2	us-gaap	Notes Payable NotesPayable	1200000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.53
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2711000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.14
CY2022Q3	RENB	Earn Out Distribution EarnOutDistribution	2762500	usd
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.21
CY2024	RENB	Extinguishment Of Contingent Consideration Liability ExtinguishmentOfContingentConsiderationLiability	419182	usd
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4673129	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3535051	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	250373	usd
CY2019Q4	RENB	Upfront Payment UpfrontPayment	10000000	usd
CY2019Q4	RENB	Payment For Expenditures PaymentForExpenditures	760000	usd
CY2021Q3	RENB	Initial Payment InitialPayment	600000	usd
CY2021Q3	RENB	Initial Payment InitialPayment	600000	usd
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2024	RENB	Segment Operating Loss SegmentOperatingLoss	81639296	usd
CY2024Q2	RENB	Segment Asset SegmentAsset	163129450	usd
CY2024	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	24557608	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2708829	usd
CY2024	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	42611000	usd
CY2024	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	11640000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	121859	usd
CY2024	RENB	Segment Operating Loss SegmentOperatingLoss	81639296	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001731122-24-001578-index-headers.html	Edgar Link	pending
0001731122-24-001578-index.html	Edgar Link	pending
0001731122-24-001578.txt	Edgar Link	pending
0001731122-24-001578-xbrl.zip	Edgar Link	pending
e5986_10-k.htm	Edgar Link	pending
e5986_ex10-10.htm	Edgar Link	pending
e5986_ex21-1.htm	Edgar Link	pending
e5986_ex23-1.htm	Edgar Link	pending
e5986_ex31-1.htm	Edgar Link	pending
e5986_ex31-2.htm	Edgar Link	pending
e5986_ex32-1.htm	Edgar Link	pending
e5986_ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
e5986_10-k_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
renb-20240630.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
renb-20240630_cal.xml	Edgar Link	unprocessable
renb-20240630_def.xml	Edgar Link	unprocessable
renb-20240630_pre.xml	Edgar Link	unprocessable
renb-20240630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RENB
RENOVARO INC. Stock $renb

2024 Q4 Form 10-K Financial Statement

#000173112224001578 Filed on October 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB RENOVARO INC. Stock $renb

2024 Q4 Form 10-K Financial Statement

#000173112224001578 Filed on October 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB
RENOVARO INC. Stock $renb